The non-clear cohort (n = 149), had a distinct profile, in that the primary kidney tumors had the highest percentage of alterations in the TERT promoter (17.4%), TP53 (13.1%), SETD2 (11.6%), VHL (8%), and ARID1A (8%) (Supplemental Table 2A). This evidence concerns the gene TP53 and kidney neoplasm.